XORTX Therapeutics Inc. (XRTX)
- Previous Close
2.5900 - Open
2.7500 - Bid --
- Ask --
- Day's Range
2.5301 - 2.7650 - 52 Week Range
1.9800 - 67.7160 - Volume
8,647 - Avg. Volume
50,059 - Market Cap (intraday)
7.713M - Beta (5Y Monthly) -0.15
- PE Ratio (TTM)
-- - EPS (TTM)
-3.6000 - Earnings Date May 15, 2024 - May 20, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
12.14
XORTX Therapeutics Inc., a late stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and acute kidney injury (AKI) associated health consequences; and XRX-225, a program for treatment of type 2 diabetic nephropathy. The company has a collaboration and license agreements with the Icahn School of Medicine to study the incidence of AKI and hyperuricemia in patients hospitalized with COVID-19; and with the University of Florida Research Foundation, Inc. XORTX Therapeutics Inc. is based in Alberta Beach, Canada.
www.xortx.comRecent News: XRTX
Performance Overview: XRTX
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: XRTX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: XRTX
Valuation Measures
Market Cap
7.65M
Enterprise Value
2.61M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.23
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-0.61
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-34.72%
Return on Equity (ttm)
-37.08%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-2.16M
Diluted EPS (ttm)
-3.6000
Balance Sheet and Cash Flow
Total Cash (mrq)
3.45M
Total Debt/Equity (mrq)
0.25%
Levered Free Cash Flow (ttm)
-4.2M